Truist cuts Boston Scientific stock price target on growth outlook

robot
Abstract generation in progress

Truist Securities has lowered its price target for Boston Scientific Corp. (NYSE:BSX) from $90 to $85, while maintaining a Buy rating. This adjustment follows the company’s first-quarter 2026 results and revised guidance, which Truist views as de-risked. Despite decelerating trends in some divisions, the firm anticipates 8% or higher organic growth for 2027-2028 and believes the stock is undervalued, supported by a low P/E ratio and attractive PEG ratio.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin